Key Takeaways
Effective CDMO governance requires clearly defined decision rights, escalation pathways, communication structures, and responsibilities across organizational boundaries.
Responsibility matrices alone may not establish who holds final authority when pharma companies and CDMOs disagree on consequential program decisions.
Predefined escalation structures can help resolve technical, quality, schedule, and resource issues before unresolved decisions create broader program delays.
Strong information governance helps preserve technical context, decision rationale, and institutional knowledge across technology transfers, handoffs, and personnel changes.
CDMO governance should evolve as programs become more complex, additional partners and functions become involved, and coordination requirements change over the product life cycle.
The Hidden Risk in a Technically Sound Partnership
The most consequential problems in outsourced drug development and manufacturing are not always technical. A contract development and manufacturing organization (CDMO) may have the right equipment, experienced scientists, appropriate quality systems, and a credible record in the relevant process, yet a program can still lose time, accumulate friction, or become difficult to steer. In those cases, the limiting factor may lie in the architecture of the relationship itself.
Pharma companies remain responsible for appropriate oversight of outsourced activities, and regulatory guidance expects responsibilities, communication processes, and controls over contracted operations to be defined rather than implicitly transferred along with the work. Pharmaceutical quality systems likewise depend on clearly established roles, appropriate communication, timely escalation of significant issues, and adequate allocation of resources.1,2
These requirements reflect an operational reality of outsourcing: two organizations must make one program work despite separate reporting structures, information systems, priorities, and chains of authority. The technical work may be divided cleanly on paper, but execution generates decisions that cross those boundaries. Who can authorize additional development work? When should an unresolved quality concern move beyond the project team? Which organization has final authority when a joint committee cannot reach agreement? Who preserves the rationale behind a decision so that it survives later personnel changes?
Those questions define the governance layer of a CDMO relationship. Weaknesses in that layer can undermine otherwise capable technical execution.
When Technical Capability Is Not the Problem
Outsourcing does not eliminate the need for active oversight by the pharma company. FDA guidance recommends written quality agreements that delineate the parties’ respective current good manufacturing practice (cGMP) responsibilities and makes clear that the product owner retains responsibility for ensuring that outsourced activities remain appropriately controlled.2 similarly places control of outsourced activities within the pharmaceutical quality system and connects that responsibility to defined roles, communication, monitoring, and management oversight.1,2
Governance can also become misaligned even when a relationship once functioned effectively. A longitudinal study of a pharmaceutical research and development alliance found that organizational restructuring within one partner changed the coordination demands of the relationship. Governance mechanisms that had worked previously became poorly matched to the altered collaboration, nearly all projects experienced substantial delays, and the parties considered ending the alliance before redesigning the governance model.3
That case was not a CDMO relationship, but it illustrates a broader point relevant to outsourcing: organizational capability depends in part on whether the structure connecting two companies still fits the work. Technical expertise creates value only when the people holding that expertise can exchange information, reach decisions, resolve conflicts, and respond to changing circumstances in time to keep the program moving.
Governance Is the Architecture Between the Organizations
In practical terms, governance defines who owns activities, who has authority over decisions, how information moves, which issues remain at the working level, what must be escalated, who resolves disagreements, and how changes in scope, risk, schedule, and resources are handled.
Companies already formalize many of these elements in collaborative agreements. A 2024 study involving 294 medical-product-industry respondents found that governance and communication processes were addressed in 77% of the initial standalone regulatory agreement examined, while 63% included responsibility-assignment matrices and 44% addressed crisis roles and responsibilities. The study also examined provisions concerning decision-making and escalation.4
Technology-transfer practice offers a more concrete picture of how governance can be structured. One model divides responsibility across technical teams, management teams, and steering committees, with different levels handling execution, coordination, strategic direction, resource allocation, project changes, and conflict escalation. The same model recommends explicit intercompany decision-making and escalation structures when transferring processes to a contract manufacturer.5
A responsibility matrix can clarify participation, but governance also has to locate authority. That becomes especially important when several functions and both organizations have legitimate interests in the same decision.
Decision Rights: Who Can Actually Say Yes?
Many programs involve numerous knowledgeable people but relatively few people with clearly defined authority. Project managers, process development scientists, analytical specialists, quality representatives, regulatory personnel, supply chain teams, commercial leaders, and executives may all have a legitimate stake in the same decision. Broad participation can improve judgment while still leaving uncertainty over who can authorize the path forward.
Evidence from biopharmaceutical strategic alliances shows that organizations address this problem by delegating decision-making authority to joint governance bodies. In an analysis of 632 alliances that used steering committees, broader alliance scope and greater task interdependence were associated with greater delegation of decision authority to those committees.6
That pattern is relevant to CDMO relationships because outsourced development and manufacturing can generate decisions whose consequences cross organizational boundaries. A technical change may affect quality, regulatory commitments, scheduling, materials, or cost. An issue that appears local to one site may have downstream implications elsewhere. Greater interdependence increases the need for mechanisms capable of making decisions across those boundaries.
Joint authority can also create another governance challenge. Steering committees often depend on consensus, and consensus can fail. The same alliance research found that contracts sometimes anticipate deadlock by specifying how unresolved decisions move upward to senior representatives or, in some cases, ultimately revert to a designated decision-maker within one partner organization.6
That makes it useful to distinguish three separate questions: who is responsible for doing the work, who is authorized to decide, and who has final authority when agreement cannot be reached.
A practical decision-rights framework can make those distinctions more explicit by defining, for each category of decision, who holds final approval authority, how quickly the other party must be informed, and who owns the associated change-control process.7 Broad language assigning oversight has limited operational value unless the relationship also specifies how that authority applies to actual categories of decisions.
Clear governance therefore establishes where authority resides even when several functions share responsibility for the underlying work. Otherwise, a program can spend valuable time determining who is entitled to make the decision before it can begin deciding what to do.
Escalation Is a Governance Mechanism, Not a Relationship Failure
Decision rights solve only part of the problem because not every issue can or should be resolved at the level where it first appears.
ICH Q10 explicitly identifies timely escalation of appropriate quality issues to the proper levels of management as part of effective pharmaceutical quality-system management.2 Technology-transfer frameworks similarly recommend defined escalation mechanisms and position steering committees as bodies that can address conflicts that lower-level teams cannot resolve.5
Effective escalation removes ambiguity about when an issue should move upward and what happens once it does. If escalation is perceived as evidence that the relationship is deteriorating, teams may delay involving people with the authority needed to resolve an issue. A different governance problem arises when working-level teams lack sufficient authority and routine disagreements move too quickly to senior leadership.
A mature escalation model should distinguish among issues that remain within the project team, issues that require functional leadership, issues that belong at a joint steering level, and issues that trigger defined final decision rights. Alliance contracts provide examples of unresolved matters moving progressively from a joint committee to senior representatives and, when necessary, to one party’s designated authority.6
A well-designed escalation structure keeps routine decisions at the working level while providing a predictable route upward for consequential or unresolved issues. The team should not have to design that route while simultaneously managing a significant technical, quality, or schedule problem.
Communication Is About Information Architecture
Few discussions of CDMO partnerships omit the need for good communication, but the phrase is too broad to guide execution unless the underlying information architecture is defined.
A weekly project meeting does not guarantee that the right information reaches the right person at the right time. Nor does a high volume of email ensure that an organization retains a coherent record of what was decided, why it was decided, and which assumptions informed the decision.
Knowledge-management practices between companies and third parties can address these risks by establishing common terminology, expectations for how information will support decisions, rules for retention, and structured methods for transferring and preserving knowledge. Informal exchanges that bypass those structures can allow relevant information to be missed or lost.8
Technology-transfer experience reinforces the connection between information flow and execution. Unclear responsibilities, opaque decision-making, and inadequate information flow have been identified as factors that can produce substantial delays and, in some cases, failed transfers.5 In complex outsourced arrangements, early and continuous communication across development, analytical, quality, manufacturing, and supply-chain functions can also support continuity as knowledge moves between organizations.9
Formal information architecture becomes especially important when personnel change. The pharmaceutical alliance that experienced severe disruption following organizational restructuring also illustrates how established personal connections and informal mechanisms can stop functioning when the organization around them changes.3
A resilient CDMO relationship cannot depend on particular individuals remembering how the partnership operates. Decisions need durable records, technical assumptions need to remain discoverable, and communication pathways need to survive turnover. Governance helps preserve that context across handoffs and personnel changes.
Competing Priorities Have to Be Governed Too
Even when both parties are committed to the same program, they may emphasize different objectives within it.
Industry survey data suggest that CDMOs and pharma companies do not always weight partnership attributes identically. In a 2025 survey of more than 100 CDMO and pharma industry leaders, CDMO respondents placed greater emphasis on speed and flexibility, while pharma respondents placed greater emphasis on reliability and communication. More than 70% of established pharma respondents in the same survey anticipated moderate-to-significant capacity constraints during 2025.10
Operations research likewise models pharmaceutical contract manufacturers as making contract-selection, scheduling, and resource-allocation decisions across multiple contracts under capacity, risk, and demand constraints.11 That evidence does not show that CDMOs routinely deprioritize individual clients or that capacity competition causes partnership failures. It does establish that outsourced manufacturing operates in an environment where finite resources must be allocated across multiple commitments.
Schedule, manufacturing capacity, cost, additional development work, regulatory commitments, and risk reduction can create tradeoffs. Governance determines how those tradeoffs are converted into an executable decision.
For example, additional technical work may reduce uncertainty while also placing pressure on a development milestone. The same tradeoff can carry different implications for quality, regulatory, technical, and commercial objectives. A functioning governance structure provides a mechanism for reconciling those implications and identifying who has authority when they point toward different courses of action.
Decision rights become most consequential at precisely these moments. Agreement is easiest when all priorities point in the same direction. Governance earns its value when they do not.
Governance Must Scale with Interdependence
Governance demands increase as organizational interfaces multiply.
This is particularly visible in programs that divide development, manufacturing, testing, or other activities across multiple external providers. In antibody–drug conjugate programs involving separate manufacturing and testing organizations, poorly defined roles, escalation pathways, and quality agreements can create delays and ambiguity, while additional organizational interfaces increase demands on governance, chemistry, manufacturing, and controls leadership, and the management of deviations and other quality events.9
The broader alliance evidence points in the same direction. As scope and task interdependence increase, organizations are more likely to delegate meaningful decision authority to joint steering structures.6 Additional interfaces create more points at which information, responsibility, timing, and assumptions have to remain aligned.
A distributed outsourcing model may still offer important technical or strategic advantages. Specialized providers can contribute expertise that a single organization may not offer. The coordination burden, however, grows with the number of boundaries the program must cross.
The same principle can apply as the program itself becomes more complex. Governance that is adequate for an early development effort involving a small technical team may need to evolve as additional functions, sites, external providers, or commercial considerations enter the program. The governance structure should remain proportionate to the interdependence it is being asked to manage.
When the Governance Model Stops Fitting the Program
Governance should not be treated as permanent infrastructure established once at the beginning of the relationship.
The longitudinal pharmaceutical alliance study provides unusually clear evidence. Internal restructuring changed the collaboration’s coordination requirements enough that existing governance mechanisms became poorly matched to the relationship. The resulting period included substantial disruption, widespread project delays, and consideration of terminating the alliance. Governance redesign later helped return the relationship to a viable development path.3
The implication for CDMO partnerships is that governance requires periodic reassessment. Changes in scope, organizational structure, personnel, external providers, resource conditions, or program maturity can alter which people need to participate, what information must move, where authority should reside, and which issues require escalation.
A governance model can therefore become inadequate without having been poorly designed initially. The relationship itself may have changed.
Periodic review should consider whether governance membership, decision authority, escalation thresholds, meeting cadence, information requirements, and conflict-resolution mechanisms still match the program. As new interfaces emerge, the architecture between the organizations needs to evolve with them.
Contracts and quality agreements establish essential boundaries, but execution determines whether those boundaries still support the way the work is being performed. Treating governance as a living operating model makes it possible to adjust the relationship before structural mismatches begin to impair execution.
The Best Partnerships Make Disagreement Executable
Strong CDMO relationships will still encounter unexpected results, deviations, schedule pressure, resource constraints, personnel changes, and disagreements about the best path forward. Governance provides the mechanisms for acting coherently when those conditions arise.
When it works, information reaches the people who need it, authority resides at an appropriate level, unresolved issues have a predictable escalation route, decisions remain documented, and the structure can adapt as the relationship changes. Working teams can resolve routine issues without constant executive intervention, while genuinely consequential decisions move to people empowered to make them.
A CDMO partnership should therefore be evaluated not only by the provider’s facilities, technologies, scientific expertise, quality record, and manufacturing experience but also by the operating system that connects the two organizations. Decision rights, escalation pathways, communication structures, and mechanisms for reconciling competing priorities help determine whether expertise on both sides translates into timely action.
The real test of governance is not whether a partnership avoids difficult decisions. It is whether the partnership can keep making them when information, interests, and priorities no longer align neatly.
References
1. Contract Manufacturing Arrangements for Drugs: Quality Agreements: Guidance for Industry. U.S. Food and Drug Administration. 23 Nov. 2016.
2. Q10 Pharmaceutical Quality System. U.S. Food and Drug Administration. 8 Apr. 2009.
3. Keller, Arne, et al. “Alliance Governance Mechanisms in the Face of Disruption.” Organization Science. 32: 1542–1570 (2021).
4. Wilhelm, Mary E, Nancy Pire-Smerkanich, and Frances J Richmond. “Standalone Regulatory Agreements for Product-Development Collaborations in the Medical Products Industry.” Therapeutic Innovation & Regulatory Science. 58: 897–909 (2024).
5. Pohlscheidt, Michael, et al. “Avoiding Pitfalls during Technology Transfer of Cell Culture Manufacturing Processes in the Pharmaceutical Industry – Mitigating Risk and Optimizing Performance.” Pharmaceutical Outsourcing. 28 Mar. 2013.
6. Hanisch, Marvin, et al. “Hybrid Administrative Interfaces: Authority Delegation and Reversion in Strategic Alliances.” Organization Science. 35: 550–572 (2024).
7. Doshi, Devanshi, and Sagi Nahum. “The Decision Rights Matrix: Making Sponsor-CDMO Governance Enforceable.” Outsourced Pharma. 29 Jul. 2026.
8. Boltres, Bettine, et al. “Expert Perspectives in KM Between Sponsors and Third Parties.” PDA Letter. 16 Apr. 2025.
9. Barry, Conor S. “The Role of Contract Manufacturing in Antibody–Drug Conjugate (ADC) Drug Substance Development – Strategies for Successful Engagement.” AAPS PharmSciTech. 27: 255 (2026).
10. “CDMO Growth Report 2025: Strategic Priorities to Stay Ahead.” Simon-Kucher and PharmaSource. 2025.
11. Elekidis, Apostolos P, and Michael C Georgiadis. “Optimal Contract Selection for Contract Manufacturing Organizations in the Secondary Pharmaceutical Industry.” Computers & Chemical Engineering. 165: 107957 (2022).
